Pulmonx (LUNG) Aandelenoverzicht
Pulmonx Corporation, een commercieel medisch technologiebedrijf dat een minimaal invasieve behandeling biedt aan patiënten met ernstig emfyseem, een vorm van chronische obstructieve longziekte. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
LUNG Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pulmonx Corporation Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$1.95 |
| 52 Week Hoogtepunt | US$2.89 |
| 52 Week Laag | US$1.13 |
| Bèta | 0.34 |
| 1 maand verandering | -12.56% |
| 3 maanden verandering | 52.34% |
| 1 Jaar Verandering | 25.81% |
| 3 jaar verandering | -81.52% |
| 5 jaar verandering | -94.94% |
| Verandering sinds IPO | -95.04% |
Recent nieuws en updates
Recent updates
Analyse-artikel • Aug 01
Earnings Release: Here's Why Analysts Cut Their Pulmonx Corporation (NASDAQ:LUNG) Price Target To US$3.40
Shareholders will be ecstatic, with their stake up 39% over the past week following Pulmonx Corporation 's...
Narratiefupdate • Jul 09
LUNG: Index Reclassification And Improved Margins Will Support Future Upside
Analysts have adjusted their Pulmonx price target from $5.17 to $3.40, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E expectations. What’s in the News for Pulmonx Pulmonx was dropped from several Russell growth oriented benchmarks, including the Russell 3000 Growth, Russell 2000 Growth, Russell 2500 Growth, Russell 3000E Growth, Russell Small Cap Comp Growth, Russell 2000 Dynamic Index, and Russell Small Cap Completeness Index.
Narratiefupdate • Jun 25
LUNG: 2026 Revenue Reaffirmation Will Support Confidence In Earnings Turnaround
Analysts have maintained their $5.00 price target on Pulmonx, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E that, taken together, support keeping fair value at $5.00. What’s in the News for Pulmonx Pulmonx reaffirmed earnings guidance for fiscal 2026, indicating revenue expectations remain unchanged.Narratiefupdate • Jun 07
LUNG: Reset Expectations And 2026 Guidance Will Underpin Turnaround Confidence
Analysts have reset their price target on Pulmonx from about $13.26 to $5.00 as they now apply lower revenue growth assumptions, slightly tighter discounting, and a modestly reduced future P/E multiple in their models. What's in the News Pulmonx reaffirmed earnings guidance for fiscal 2026 and said it continues to expect full-year revenue in the range of $90 million to $92 million.Narratiefupdate • May 24
LUNG: Fundamentals Refocus And Internal Fixes Will Support Future Turnaround Confidence
Analysts recently cut their Pulmonx price target to $5 from $6, pointing to Q4 results that were largely in line with expectations while management works through internal issues and refocuses on the fundamentals that previously supported the business. Analyst Commentary Recent research points to a more measured, but still constructive, stance toward Pulmonx.Narratiefupdate • May 02
LUNG: Execution Improvements And Fundamentals Focus Will Support Future Turnaround Confidence
Analysts have trimmed their price target on Pulmonx to $5 from $6, reflecting Q4 results that were largely in line and management's efforts to address internal issues while refocusing on the fundamentals that previously supported the business. Analyst Commentary Bullish analysts are emphasizing that the trimmed US$5 price target still reflects confidence that Pulmonx can execute on its plan to resolve internal issues and refocus on the fundamentals that previously supported the business.Narratiefupdate • Apr 18
LUNG: Fundamental Reset And Cleaner Execution Will Support Future Upside
Analysts have trimmed their Pulmonx price target to $5 from $6, citing largely in line Q4 results, management's explanation of last year's internal issues, and the company's renewed focus on the fundamentals that supported its earlier success. Analyst Commentary Bullish Takeaways Bullish analysts view the reset to a US$5 price target as reflecting a more grounded expectation for execution, with Q4 results described as largely in line rather than a negative surprise.Narratiefupdate • Apr 04
LUNG: Cleaner Execution And Fundamentals Refocus Will Support Future Upside
Analysts have trimmed their price target on Pulmonx to $5 from $6, pointing to Q4 results that were largely in line and to management's efforts to fix last year's internal issues while refocusing on the core fundamentals of the business. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Q4 results being largely in line supports the current valuation reset, even with the lower US$5 price target.Narratiefupdate • Mar 21
LUNG: Cleaner Execution And 2026 Revenue Guidance Will Support Future Upside
Analysts have trimmed their price target on Pulmonx to about $5.17 from $5.75, reflecting updated views on revenue growth, profit margin expectations, and the impact of recent operational issues highlighted in Q4 commentary. Analyst Commentary Recent research suggests that the lower price target reflects a reset of expectations around execution while still acknowledging the core business case.Narratiefupdate • Mar 06
LUNG: Operational Reset And Fundamentals Focus Will Support Turnaround Confidence
Analysts have lowered their price target on Pulmonx by $1 to $5, citing Q4 results that were broadly in line with expectations, while management works through internal issues and refocuses on the fundamentals that previously supported the business. Analyst Commentary Recent research points to a more cautious, but still constructive, stance on Pulmonx.Narratiefupdate • Feb 20
LUNG: Refined Risk And Margin Outlook Will Support Turnaround Confidence
Analysts have adjusted their Pulmonx price targets to reflect updated assumptions on discount rate, revenue growth, profit margin, and future P/E, keeping fair value around $13.49 while fine tuning the risk and earnings profile in their models. Valuation Changes Fair Value: Model fair value is unchanged at $13.49, indicating updated inputs did not shift the overall valuation level.Analyse-artikel • Feb 11
Pulmonx Corporation (NASDAQ:LUNG) Not Doing Enough For Some Investors As Its Shares Slump 29%
The Pulmonx Corporation ( NASDAQ:LUNG ) share price has fared very poorly over the last month, falling by a substantial...Narratiefupdate • Feb 06
LUNG: Firm Guidance And Margins Will Support Future Upside Potential
Analysts have kept their Pulmonx fair value estimate steady at US$5.75, with a slightly higher discount rate and P/E assumptions guiding the updated price target rationale. What's in the News Pulmonx issued new earnings guidance for full year 2025, setting an expected total revenue range of US$89 million to US$90 million.Narratiefupdate • Jan 23
LUNG: Prior Leadership Return Will Drive Confidence In Turnaround Story
Narrative Update on Pulmonx Analysts have cut their price target on Pulmonx from $8 to $4, pointing to revised fair value assumptions and a lower future P/E multiple. At the same time, they highlight prior leadership returning and continued confidence in the Zephyr valves concept and the broader market opportunity.Analyse-artikel • Jan 10
Does Pulmonx (NASDAQ:LUNG) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Narratiefupdate • Jan 08
LUNG: Returning Leadership And Clinical Traction Will Support Future Upside Potential
Analysts have trimmed their price target on Pulmonx to US$4.00 from US$8.00, citing a reassessment of valuation, the return of prior leadership, and ongoing confidence in the clinical proof of concept for Zephyr valves and the broader market opportunity. Analyst Commentary Recent research commentary focuses on how the lower price target, leadership changes, and clinical track record of Zephyr valves fit together for investors weighing risk and potential reward.Narratiefupdate • Dec 24
LUNG: Returning Leadership Will Drive Confidence Amid Near-Term Execution Uncertainty
Analysts have reduced their price target on Pulmonx to approximately $4.00 from $8.00, citing near term uncertainty around leadership changes but continued confidence in the long term opportunity, supported by Zephyr valve clinical validation and the broader product pipeline. Analyst Commentary Bullish Takeaways Bullish analysts highlight that even after the reduced price target, the implied upside still represents roughly a potential doubling from recent after hours trading levels, which underscores a favorable risk reward profile.Narratiefupdate • Dec 10
LUNG: Returning Leadership Will Drive Confidence And Unlock Significant Upside Ahead
Analysts have reduced their price target on Pulmonx to about $4 from roughly $8, citing a lower discount rate along with confidence in returning leadership, robust clinical validation of Zephyr valves, and a solid market and pipeline opportunity that they still see as supporting substantial upside from current levels. Analyst Commentary Bullish Takeaways Bullish analysts highlight that the lowered price target still implies meaningful upside from current trading levels, suggesting the market may be underestimating the company’s long term earnings potential.Analyse-artikel • Dec 05
Improved Revenues Required Before Pulmonx Corporation (NASDAQ:LUNG) Stock's 26% Jump Looks Justified
The Pulmonx Corporation ( NASDAQ:LUNG ) share price has done very well over the last month, posting an excellent gain...Narratiefupdate • Nov 26
LUNG: Returning Leadership Will Restore Confidence And Unlock Upside In Coming Year
Analysts have revised their price target for Pulmonx downward from $8 to $4 per share. They cite ongoing confidence in the company's clinical proof of concept and market opportunities, even in light of unexpected executive changes.Narratiefupdate • Nov 12
LUNG: Leadership Transition Will Drive Renewed Execution Strength In The Coming Year
Analysts have revised Pulmonx’s price target downward from $8.00 to $4.00. They cite both leadership changes and ongoing belief in the company’s clinical achievements and long-term market potential as rationale for the adjustment.Narratiefupdate • Oct 29
Leadership Return And Clinical Strength Will Drive Long-Term Market Opportunity
Analysts have lowered their price target for Pulmonx from $6.75 to $5.75, reflecting adjusted expectations on revenue growth and valuation. They remain optimistic, however, due to strong clinical evidence and a promising leadership transition.Analyse-artikel • Aug 28
Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyse-artikel • Jul 24
Pulmonx Corporation (NASDAQ:LUNG) Soars 47% But It's A Story Of Risk Vs Reward
Those holding Pulmonx Corporation ( NASDAQ:LUNG ) shares would be relieved that the share price has rebounded 47% in...Analyse-artikel • May 26
Pulmonx Corporation (NASDAQ:LUNG) Stock's 40% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Unfortunately for some shareholders, the Pulmonx Corporation ( NASDAQ:LUNG ) share price has dived 40% in the last...Analyse-artikel • Apr 11
Not Many Are Piling Into Pulmonx Corporation (NASDAQ:LUNG) Stock Yet As It Plummets 29%
The Pulmonx Corporation ( NASDAQ:LUNG ) share price has fared very poorly over the last month, falling by a substantial...
Nieuw narratief • Apr 01
LungTrax And Global Expansion Will Broaden Market Access
Expansion into new markets and innovative tools like LungTrax could grow patient volume, boosting revenue and operational efficiency.Analyse-artikel • Feb 21
Pulmonx Corporation (NASDAQ:LUNG) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Shareholders of Pulmonx Corporation ( NASDAQ:LUNG ) will be pleased this week, given that the stock price is up 19% to...Analyse-artikel • Feb 07
Many Still Looking Away From Pulmonx Corporation (NASDAQ:LUNG)
There wouldn't be many who think Pulmonx Corporation's ( NASDAQ:LUNG ) price-to-sales (or "P/S") ratio of 3.2x is worth...Analyse-artikel • Oct 22
Not Many Are Piling Into Pulmonx Corporation (NASDAQ:LUNG) Stock Yet As It Plummets 27%
The Pulmonx Corporation ( NASDAQ:LUNG ) share price has fared very poorly over the last month, falling by a substantial...Analyse-artikel • Oct 02
Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyse-artikel • Aug 15
Pulmonx Corporation (NASDAQ:LUNG) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Unfortunately for some shareholders, the Pulmonx Corporation ( NASDAQ:LUNG ) share price has dived 26% in the last...Seeking Alpha • Jul 21
Pulmonx: Low Bar For Q2 Earnings
Summary New CEO suggests status quo with respect to corporate strategy. Upcoming Q2 earnings have low expectations, which could provide a short-term positive catalyst. However, longer-term, the main issue with Pulmonx remains the mismatch between revenues and expenses. Read the full article on Seeking AlphaAnalyse-artikel • Jun 07
Slammed 26% Pulmonx Corporation (NASDAQ:LUNG) Screens Well Here But There Might Be A Catch
The Pulmonx Corporation ( NASDAQ:LUNG ) share price has fared very poorly over the last month, falling by a substantial...Rendement voor aandeelhouders
| LUNG | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | -1.5% | 0.7% | -1.1% |
| 1Y | 25.8% | -15.8% | 11.7% |
Rendement versus industrie: LUNG overtrof de US Medical Equipment industrie, die het afgelopen jaar een rendement -15.8 % opleverde.
Rendement versus markt: LUNG overtrof de US markt, die het afgelopen jaar een rendement opleverde van 11.7 %.
Prijsvolatiliteit
| LUNG volatility | |
|---|---|
| LUNG Average Weekly Movement | 15.8% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: De aandelenkoers van LUNG is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 16% ) van LUNG is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1995 | 296 | Glen French | pulmonx.com |
Pulmonx Corporation, een commercieel medisch technologiebedrijf dat een minimaal invasieve behandeling biedt voor patiënten met ernstig emfyseem, een vorm van chronische obstructieve longziekte. Het bedrijf biedt de Zephyr Endobronchial Valve en het Chartis Pulmonary Assessment System, een ballonkatheter en consolesysteem met flow- en druksensoren die worden gebruikt om de aanwezigheid van collaterale ventilatie te beoordelen. Het bedrijf biedt ook het LungTraX Platform, een cloud-gebaseerde kwantitatieve computertomografie-analyseservice die artsen voorziet van meerdere producten, zoals LungTraX Connect om de efficiëntie van de workup te verbeteren; LungTraX Detect om de identificatie van patiënten mogelijk te maken; en StratX Lung report dat is ontworpen voor oplossingen die informatie bevatten over de vernietiging van emfyseem, de volledigheid van de fissuur en het kwabvolume om de doelkwabben voor behandeling met Zephyr Valves te helpen identificeren.
Pulmonx Corporation Samenvatting
| LUNG fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$82.03m |
| Inkomsten(TTM) | -US$48.12m |
| Inkomsten(TTM) | US$87.44m |
1.0x
P/S-verhouding-1.7x
Koers/WinstverhoudingIs LUNG overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| LUNG resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$87.44m |
| Kosten van inkomsten | US$20.06m |
| Brutowinst | US$67.38m |
| Overige uitgaven | US$115.50m |
| Inkomsten | -US$48.12m |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -1.12 |
| Brutomarge | 77.06% |
| Nettowinstmarge | -55.03% |
| Schuld/Eigen Vermogen Verhouding | 95.8% |
Hoe presteerde LUNG op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/16 06:48 |
| Aandelenkoers aan het einde van de dag | 2026/09/16 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Pulmonx Corporation wordt gevolgd door 10 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Travis Steed | BofA Global Research |
| William Plovanic | Canaccord Genuity |
| John Young | Canaccord Genuity |